Thomas S, Bae C, Joy-Ann T, Traverse W. Behcet's-like syndrome following pembrolizumab: An immune-related adverse event associated with programmed death receptor-1 inhibitor therapy. J Oncol Pharm Pract. 2020 Jun; 26(4):995-999.